{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:59:54Z","timestamp":1765609194312},"reference-count":39,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:p>The incidence and role of p53 abnormalities have not been reported in splenic lymphoma with villous lymphocytes (SLVL), the leukemic counterpart of splenic marginal zone lymphoma. Because p53 abnormalities correlate with progressive and refractory disease in cancer and isochromosome 17q has been described in SLVL, a low-grade lymphoma that behaves aggressively in a minority of patients, this study investigated p53 changes by molecular and immunophenotypic methods in samples from 59 patients. The p53 deletion was analyzed by fluorescence in situ hybridization, and p53 protein expression was assessed by immunocytochemistry in 35 of 59 cases and by flow cytometry in 20 of 35 patients. Ten patients (17%) had a monoallelic p53 loss, 3 (9%) of 35 nuclear protein expression by immunocytochemistry, and 2 (10%) of 20 by flow cytometry. Two patients had both deletion and protein expression. Direct sequencing of all p53 exons was used to delineate mutations in 9 of 11 patients with an identified abnormality. Mutations, both compromising p53 DNA binding, were identified in the 2 patients with deletion and protein accumulation. Kaplan-Meier analysis revealed a significantly worse survival for patients with p53 abnormalities. Although p53 abnormalities are infrequent in SLVL, they underlie a more aggressive disease course and poor prognosis.<\/jats:p>","DOI":"10.1182\/blood.v97.11.3552","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"3552-3558","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["p53 abnormalities in splenic lymphoma with villous lymphocytes"],"prefix":"10.1182","volume":"97","author":[{"given":"Alicja M.","family":"Gruszka-Westwood","sequence":"first","affiliation":[{"name":"From the Academic Department of Haematology and Cytogenetics, Institute of Cancer Research\/Royal Marsden NHS Trust, London, United Kingdom; and Cancer Gene Cloning Centre, Institute of Cancer Research, Sutton, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifat A.","family":"Hamoudi","sequence":"additional","affiliation":[{"name":"From the Academic Department of Haematology and Cytogenetics, Institute of Cancer Research\/Royal Marsden NHS Trust, London, United Kingdom; and Cancer Gene Cloning Centre, Institute of Cancer Research, Sutton, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estella","family":"Matutes","sequence":"additional","affiliation":[{"name":"From the Academic Department of Haematology and Cytogenetics, Institute of Cancer Research\/Royal Marsden NHS Trust, London, United Kingdom; and Cancer Gene Cloning Centre, Institute of Cancer Research, Sutton, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Tuset","sequence":"additional","affiliation":[{"name":"From the Academic Department of Haematology and Cytogenetics, Institute of Cancer Research\/Royal Marsden NHS Trust, London, United Kingdom; and Cancer Gene Cloning Centre, Institute of Cancer Research, Sutton, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[{"name":"From the Academic Department of Haematology and Cytogenetics, Institute of Cancer Research\/Royal Marsden NHS Trust, London, United Kingdom; and Cancer Gene Cloning Centre, Institute of Cancer Research, Sutton, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217160573600_B1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V83.6.1558.1558","article-title":"The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders.","volume":"83","author":"Matutes","year":"1994","journal-title":"Blood."},{"key":"2020021217160573600_B2","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1182\/blood.V84.11.3828.bloodjournal84113828","article-title":"The histopathology of splenic lymphoma with villous lymphocytes.","volume":"84","author":"Isaacson","year":"1994","journal-title":"Blood."},{"key":"2020021217160573600_B3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","article-title":"Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases.","volume":"78","author":"Mulligan","year":"1991","journal-title":"Br J Haematol."},{"key":"2020021217160573600_B4","first-page":"73","volume-title":"Prognostic markers in patients with splenic lymphoma with villous lymphocytes. British Society for Haematology Annual Meeting. Br J Haematol. Bournemouth","author":"Parry-Jones","year":"2000"},{"key":"2020021217160573600_B5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2141.1993.tb03337.x","article-title":"Cytogenetic studies in splenic lymphoma with villous lymphocytes.","volume":"85","author":"Oscier","year":"1993","journal-title":"Br J Haematol."},{"key":"2020021217160573600_B6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-230X(08)60785-X","article-title":"p53 and human cancer: the first ten thousand mutations.","volume":"77","author":"Hainaut","year":"2000","journal-title":"Adv Cancer Res."},{"key":"2020021217160573600_B7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division.","volume":"88","author":"Levine","year":"1997","journal-title":"Cell."},{"key":"2020021217160573600_B8","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer Res."},{"key":"2020021217160573600_B9","first-page":"1149","article-title":"Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.","volume":"58","author":"Ahnen","year":"1998","journal-title":"Cancer Res."},{"key":"2020021217160573600_B10","first-page":"107","article-title":"Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma.","volume":"14","author":"Osada","year":"1999","journal-title":"Anti-Cancer Drug Design."},{"key":"2020021217160573600_B11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/10428199809057575","article-title":"Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and P53 in non-Hodgkin's lymphomas.","volume":"30","author":"Korkolopoulou","year":"1998","journal-title":"Leuk Lymphoma."},{"key":"2020021217160573600_B12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/10428199809058389","article-title":"Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.","volume":"29","author":"Navaratnam","year":"1998","journal-title":"Leuk Lymphoma."},{"key":"2020021217160573600_B13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V89.2.601","article-title":"Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.","volume":"89","author":"Wilson","year":"1997","journal-title":"Blood."},{"key":"2020021217160573600_B14","first-page":"1085","article-title":"Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.","volume":"5","author":"Moller","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2020021217160573600_B15","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<718::AID-CNCR22>3.0.CO;2-Y","article-title":"p53 gene mutations and rearrangements in non-Hodgkin's lymphoma.","volume":"85","author":"Chen","year":"1999","journal-title":"Cancer."},{"key":"2020021217160573600_B16","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1182\/blood.V86.12.4587.bloodjournal86124587","article-title":"The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma.","volume":"86","author":"Du","year":"1995","journal-title":"Blood."},{"key":"2020021217160573600_B17","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood."},{"key":"2020021217160573600_B18","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.","volume":"90","author":"Koduru","year":"1997","journal-title":"Blood."},{"key":"2020021217160573600_B19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.1997.3143131.x","article-title":"Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization.","volume":"98","author":"Clodi","year":"1997","journal-title":"Br J Haematol."},{"key":"2020021217160573600_B20","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood.V84.8.2412.2412","article-title":"p53 in hematologic malignancies.","volume":"84","author":"Imamura","year":"1994","journal-title":"Blood."},{"key":"2020021217160573600_B21","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia."},{"key":"2020021217160573600_B22","first-page":"57","article-title":"The immunophenotype of hairy cell leukemia (HCL): proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes.","volume":"14(suppl 1)","author":"Matutes","year":"1994","journal-title":"Leuk Lymphoma."},{"key":"2020021217160573600_B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0022-1759(92)90122-A","article-title":"An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53.","volume":"151","author":"Vojtesek","year":"1992","journal-title":"J Immunol Methods."},{"key":"2020021217160573600_B24","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/MCB.10.10.5502","article-title":"Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.","volume":"10","author":"Cheng","year":"1990","journal-title":"Mol Cell Biol."},{"key":"2020021217160573600_B25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/0888-7543(89)90129-8","article-title":"Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.","volume":"5","author":"Orita","year":"1989","journal-title":"Genomics."},{"key":"2020021217160573600_B26","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"p53 abnormalities in B-cell prolymphocytic leukemia.","volume":"89","author":"Lens","year":"1997","journal-title":"Blood."},{"key":"2020021217160573600_B27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1440-1827.1998.tb03822.x","article-title":"p53 protein expression in non-Hodgkin's lymphomas is infrequently related to p53 gene mutations.","volume":"48","author":"Oka","year":"1998","journal-title":"Pathol Int."},{"key":"2020021217160573600_B28","first-page":"1342","article-title":"Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.","volume":"8","author":"Lepelley","year":"1994","journal-title":"Leukemia."},{"key":"2020021217160573600_B29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1515\/BC.1999.108","article-title":"Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.","volume":"380","author":"Roemer","year":"1999","journal-title":"Biol Chem."},{"key":"2020021217160573600_B30","first-page":"6588","article-title":"Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.","volume":"52","author":"Nakai","year":"1992","journal-title":"Cancer Res."},{"key":"2020021217160573600_B31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations [see comments].","volume":"265","author":"Cho","year":"1994","journal-title":"Science."},{"key":"2020021217160573600_B32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/nar\/26.1.205","article-title":"IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools.","volume":"26","author":"Hainaut","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"2020021217160573600_B33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.","volume":"92","author":"Drach","year":"1998","journal-title":"Blood."},{"key":"2020021217160573600_B34","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood."},{"key":"2020021217160573600_B35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2401272","article-title":"Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome.","volume":"13","author":"Callet Bauchu","year":"1999","journal-title":"Leukemia."},{"key":"2020021217160573600_B36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood.V84.1.270.270","article-title":"Frequent p53 gene involvement in splenic B-cell leukemia\/lymphomas of possible marginal zone origin.","volume":"84","author":"Baldini","year":"1994","journal-title":"Blood."},{"key":"2020021217160573600_B37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.1997.3973215.x","article-title":"Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations.","volume":"99","author":"Baldini","year":"1997","journal-title":"Br J Haematol."},{"key":"2020021217160573600_B38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0046-8177(99)90031-X","article-title":"Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant?","volume":"30","author":"Lloret","year":"1999","journal-title":"Hum Pathol."},{"key":"2020021217160573600_B39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/mp.51.5.262","article-title":"Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas.","volume":"51","author":"Sol Mateo","year":"1998","journal-title":"Mol Pathol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/11\/3552\/1674445\/h8110103552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/11\/3552\/1674445\/h8110103552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:02:44Z","timestamp":1581548564000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/11\/3552\/107550\/p53-abnormalities-in-splenic-lymphoma-with-villous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.11.3552","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6,1]]}}}